tarloxotinib   Click here for help

GtoPdb Ligand ID: 9409

Synonyms: PR610 | tarloxotinib cation | TH-4000
Compound class: Synthetic organic
Comment: Tarloxotinib (TH-4000) is a hypoxia-activated prodrug (HAP) [1] being developed by Threshold Pharmaceuticals. Delivered as the bromide salt (PubChem CID 51038315) as described in its INN record. The compound undergoes activation selectively within the hypoxic tumour compartment to produce an irreversible pan-ErbB tyrosine-kinase inhibitor, represented by TH-4000E [1]. The 4-nitroimidazole trigger on the tertiary amine side chain facilitates activation. This is one of the first molecularly targeted HAPs to be developed.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 2
Rotatable bonds 10
Topological polar surface area 140.76
Molecular weight 600.09
XLogP 3.45
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES O=C(Nc1ncc2c(c1)c(ncn2)Nc1ccc(c(c1)Br)Cl)C=CC[N+](Cc1n(C)cnc1[N+](=O)[O-])(C)C
Isomeric SMILES O=C(Nc1ncc2c(c1)c(ncn2)Nc1ccc(c(c1)Br)Cl)/C=C/C[N+](Cc1n(C)cnc1[N+](=O)[O-])(C)C
InChI InChI=1S/C24H23BrClN9O3/c1-33-14-30-24(34(37)38)20(33)12-35(2,3)8-4-5-22(36)32-21-10-16-19(11-27-21)28-13-29-23(16)31-15-6-7-18(26)17(25)9-15/h4-7,9-11,13-14H,8,12H2,1-3H3,(H-,27,28,29,31,32,36)/p+1/b5-4+
No information available.
Summary of Clinical Use Click here for help
Tarloxotinib (TH-4000) failed to show clinical efficacy in Phase 2 clinical trial for EGFR mutant, T790M-negative NSCLC (NCT02454842) and recurrent or metastatic squamous cell carcinoma of the head and neck or skin (NCT02449681). Development was subsequently terminated.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02449681 Study for Treatment of Patients With Recurrent or Metastatic SCCHN or SCCS Phase 2 Interventional Threshold Pharmaceuticals
NCT02454842 Study for Treatment of Patients With EGFR Mutant, T790M-negative NSCLC Phase 2 Interventional Threshold Pharmaceuticals